Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab Combined With Immunotherapy and Chemotherapy in LA-HNSCC
NCT07601737Phase 2Recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Apr 2026
- Primary completion
- Apr 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nimotuzumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Event-Free Survival at 2 years. Started Apr 2026; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07601737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07601737.